Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of IMM0306 injection in relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma
CTR20192612Phase 2Active
- Sponsor
- ImmuneOnco
- Start
- May 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of IMM0306S in mature B-cell lymphoma, follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL), mantle cell lymphoma (MCL), extranodal marginal zone B-cell lymphoma (EMZL), sponsored by ImmuneOnco. Started May 2020; status: active.
02
Drugs
IMM0306S
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)mantle cell lymphoma (MCL)extranodal marginal zone B-cell lymphoma (EMZL)
Beyond the preview
Go deeper on CTR20192612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192612.